aTyr Pharma Inc.
3545 John Hopkins Road, Suite 250
San Diego
California
92121
United States
258 articles about aTyr Pharma Inc.
-
aTyr Pharma Provides Corporate Update And Outlook For 2016
1/11/2016
-
aTyr Pharma To Present At 34th Annual J.P. Morgan Healthcare Conference
1/7/2016
-
aTyr Pharma Appoints Sanuj Ravindran, M.D., As Chief Business Officer
1/7/2016
-
aTyr Pharma Added To NASDAQ Biotechnology Index
12/16/2015
-
aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine For GMP Process Development And For Potential Treatment Of Severe Lung Diseases
11/11/2015
-
aTyr Pharma Announces Third Quarter 2015 Operating Results
11/11/2015
-
aTyr Pharma To Host Breakout Session At The 6th Annual World Orphan Drug Congress
11/10/2015
-
aTyr Pharma Initiates Phase 1b/2 Clinical Trial In Patients With Early Onset FSHD
11/9/2015
-
Nature Release: Publication In aTyr Pharma Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway In Neuronal Biology
11/4/2015
-
aTyr Pharma To Present At 24th Annual Credit Suisse Healthcare Conference
11/3/2015
-
aTyr Pharma Initiates Phase 1b/2 Clinical Trial For Patients With Limb Girdle Muscular Dystrophy 2B
10/13/2015
-
aTyr Pharma Announces Presentations At The World Muscle Congress And 10th International Symposium On Aminoacyl-Trna Synthetases (AARS2015)
9/25/2015
-
aTyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris For Treatment Of Adult Patients With FSHD
9/9/2015
-
aTyr Pharma Announces Transitions In Clinical Development & Operations
7/20/2015
-
aTyr Pharma Announces Change In Leadership
7/14/2015
-
aTyr Pharma Added To Russell 2000, 3000 And Global Indexes
6/29/2015
-
aTyr Pharma Announces First Quarter 2015 Operating Results
6/19/2015
-
aTyr Pharma To Present At 35th Annual William Blair Growth Stock Conference
6/3/2015
-
aTyr Pharma Announces Closing Of Initial Public Offering
5/13/2015
-
aTyr Pharma Announces Pricing Of Initial Public Offering
5/7/2015